What evidence supports the claim that flu vaccines reduce hospitalizations and deaths in children during the 2025 season?
Executive summary
Robust, real-world surveillance and vaccine-effectiveness (VE) studies from 2024–2025 and early 2025–2026 show consistent, sometimes large reductions in influenza-associated hospitalizations in children after vaccination, with multiple datasets estimating vaccine protection in children often in the 50–75% range for preventing hospitalization and emergency-department attendance; those studies are observational and contingent on circulating virus match, so uncertainty remains about exact magnitudes in any single season [1] [2] [3] [4].
1. Real-world VE studies give the primary evidence: reduced hospitalizations in children
Large, multi-country sentinel surveillance analyses pooling outpatient and severe acute respiratory infection (SARI) data found that Southern Hemisphere 2025 vaccines reduced medically attended influenza and hospitalizations by roughly half overall, with VE against hospitalization in young children reported at about 51% in that pooled evaluation [1] [2]. Similarly, interim analyses and national VE networks in the United States for the 2024–2025 season reported meaningful reductions in hospitalizations attributable to vaccination, with hospital-based VE point estimates for children and adolescents often well above the threshold for meaningful clinical impact [5] [6].
2. Independent national analyses support high pediatric protection early in 2025–26
Early-season data from England and preprint national surveillance reported VE of roughly 70–75% for preventing emergency-department attendance and hospital admission among children and adolescents in the 2025–26 Northern Hemisphere season, a level consistent with several contemporary reports and expert summaries [3] [7] [4]. These country-level results align with historical patterns where pediatric VE against severe outcomes frequently exceeds adult estimates.
3. Impact translated into prevented hospitalizations and deaths in population estimates
CDC modeling and aggregate burden estimates attribute thousands of pediatric hospitalizations and dozens to hundreds of pediatric deaths prevented by vaccination in recent seasons; for example, the agency estimated that vaccination prevented over 11,000 hospitalizations and 173 deaths among U.S. children under 5 in the 2023–24 season and similarly substantial numbers in older pediatric groups [8]. Such burden-prevention figures come from combining VE estimates with surveillance-based disease burden calculations.
4. How the evidence is generated — strengths and methodological limits
Most contemporary VE estimates come from test-negative case-control designs and networked surveillance (e.g., IVY, VISION, U.S. Flu VE, REVELAC-i) that compare vaccination odds in test-positive versus test-negative patients and adjust for confounders; these methods are efficient for real-world impact estimation across large populations and settings [1] [5] [6]. However, these are observational studies subject to biases (healthcare-seeking differences, misclassification of vaccination status) and provide VE point estimates with confidence intervals that sometimes cross the null in smaller subgroup analyses [5] [6].
5. Where uncertainty remains — viral mismatch, seasonality, and evidence gaps on deaths
Effect size depends heavily on which influenza subtypes circulate and how well vaccine strains match them; experts warned that a reduced match to emerging H3N2 subclade K could lower protection against infection even while retaining protection against severe outcomes, creating season-to-season variability in VE [4] [7]. Randomized controlled trials in children have historically been too small to reliably detect effects on rare outcomes like hospitalization or death, meaning estimates of mortality reduction rely on observational inference and modeled burden estimates rather than large RCTs [8].
6. Synthesis — a confident but calibrated conclusion
Collective, contemporary evidence from multiple surveillance networks and national analyses establishes that influenza vaccination in 2024–2026 reduced pediatric hospitalizations — commonly by about half in pooled estimates and by 50–75% in some national early-season reports for children — and that substantial numbers of hospitalizations and deaths have been averted in recent seasons according to CDC burden models [1] [2] [3] [8]. Nevertheless, the magnitude for any given season (including 2025) will vary with viral evolution and vaccine match, and rare outcomes such as pediatric deaths are inferred from modeled combinations of VE and burden rather than direct RCT evidence [4] [8].